A retrospective analysis of clinical charts across multiple institutions has found that transitioning patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to receive lanreotide after octreotide can be a potential therapeutic option.
A retrospective analysis of clinical charts across multiple institutions has found that transitioning patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to receive lanreotide (LAN) after octreotide (OCT) can be a potential therapeutic option.
The results were released during a poster session at the North American Neuroendocrine Tumor Society annual meeting, held October 4-6 in Seattle, Washington.
Researchers at the various institutions who participated in the study reviewed charts of adult patients with locally advanced GEP-NETs who received ≥90 days OCT monotherapy followed by ≥90 days LAN monotherapy. Patient demographic and clinical data, as well as treatment responses, treatment duration, reason for change of treatment, and clinical progression were gathered. The outcomes of interest were clinically defined progressive disease (CDPD) and clinical progression-free duration (CPFD); these were based on radiological imaging, symptom control, biomarkers, or clinical judgement.
Of the 91 patient charts that were reviewed, about 60% (n = 63) were female, and the average age at diagnosis was 57.7 years (standard deviation [SD], 10.9). A majority of patients had advanced disease when they first presented, either stage IV disease (71%) or liver metastases (71.4%), and most had functional disease at diagnosis (60.4%). Primary tumor sites were the small intestine (63.7%) or pancreas (14.3%).
The analysis helped researchers identify several reasons for the transition to LAN:
While 30.8% of OCT patients had CDPD when they started LAN treatment, the number reduced to 24.2% when patients were evaluated at a median follow-up of 59.5 months (interquartile range, 41.4-94.9). CPFD on LAN (n = 91) was 23.7 months (95% CI, 20.2-NE). For CDPD OCT patients (n = 28) and patients who had stable disease (n = 52), CPFD was 15.2 months (95% CI, 11.4-NE) and 24 months (95% CI, 24.7-NE), respectively.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More